Government Laboratory Worker with Lung Cancer: Comparing Risks from Beryllium, Asbestos, and Tobacco Smoke.
A 73 year-old-male first sought medical care for his current condition 6 months before our evaluation, when he presented to his private physician complaining of a 1-year history of cough and dyspnea. A chest X ray at that time revealed bilateral interstitial fibrosis and a left-sided pleural density showed marked pleural fibrosis associated with a malignant neoplasm most consistent with poorly differentiated adenocarcinoma. Periodic acid-Schiff staining showed sparse intracytoplasmic mucin in the neoplastic cells, which suggested an adenocarcinoma. The surrounding lung tissue displayed focal interstitial fibrosis and numerous non-caseating granulomas. Based on the patient's history of beryllium work, a lymphocyte proliferation test was obtained and was positive for beryllium sensitization. Abdominal computed tomography (CT), brain magnetic resonance imaging (MRI), and whole-body radionuclide scans showed no evidence of an extrapulmonary primary tumor. A chest CT showed diffuse interstitial markings, a loculated pleural effusion, a tiny speculated density in the left subapical region, and mild mediastinal adenopathy.
The patient's occupational history is remarkable because he spent the majority of his working life at a single governmental research facility specializing in weapons development. He began working there in 1959 and spent the first 3 years as a maintenance mechanic, repairing and maintaining air conditioners, chillers, boilers, and other facility operation. In 1962, he began working as a chemistry technician where he frequently worked directly with beryllium. This job involved pouring and measuring beryllium oxide, growing beryllium crystals, and molding beryllium oxide into experimental nuclear reactor parts using hot presses and graphite dyes. He was also involved in both the setup and cleanup of numerous experiments using beryllium, including cleaning machinery and bagging contaminated parts. The patient worked with beryllium on almost a daily basis from 1962 until 1964, and then for a few weeks per year until 1975.
The patient stated that his work with beryllium was mostly done in a controlled environment. For example, the pouring and measuring of beryllium oxide was always done under a vacuum hood. The growing of beryllium crystals and the experiments involving beryllium were typically performed in an enclosed box or vacuum bag. The patient also reported that when handling contaminated parts or cleaning after an experiment, he typically wore a respirator, gloves, and a lab coat. Despite these controls, the patient did not remember any strict formal decontamination procedures. He did not always immediately wash or shower after this work, and he frequently took his work clothes home. The patient also stated that although he occasionally wore a respirator, it may not have fit well because he frequently smelled fumes while wearing it.
During this same period, the patient was also exposed to asbestos. This occurred as he removed, cut, and replaced asbestos insulation used in furnaces. He did this approximately 1 or 2 hr/week; visible dust was produced during these procedures until strict controls were enforced in the early 1970s. From 1975 until 1987, the patient worked as a research technician in the tritium laboratory at the same facility, where he worked on various testing projects involving experimental nuclear reactors. He wore a radiation badge, but denied ever having "burned out" (reached acute or cumulative badge reading above the facility's allowable limits). He also denied ever being involved in any acute radiation accidents. The patient's cumulative radiation exposure was unknown, but cumulative radiation levels have been determined in other workers at this facility, and have generally been well below those associated with cancer (1,2).
The patient's medical history is noncontributory except that he smoked one pack of cigarettes per day from 15 to 37 years of age. He had no close family members who smoked and no other known occupational or environmental exposures to lung carcinogens such as arsenic, chloromethyl ethers, or radon.
Estimating exposure. Based on the patient's history, the most obvious causes of his cancer seemed to be tobacco smoke, beryllium, and asbestos. We used several methods to estimated the patient's exposure and subsequent lung cancer risk for each agent. For tobacco smoke, a relatively precise assessment of exposure could be estimated because the patient was forthcoming about his past smoking history, and this history correlated well with reports in his past medical records. For beryllium and asbestos, however, personal exposure data were lacking, so less direct methods were needed to estimated the patient's exposure to these agents.
According to a verbal report from the patient's former employer, general area air levels of beryllium in the patient's work site never exceeded the threshold limit value of 2 [micro]g/[m.sup.3]. Unfortunately, the extent and accuracy of these readings is unknown. Air sampling may miss short-term, high-dose exposures, especially in areas away from the sampling device (3-5). Routine air monitoring may also miss exposures occurring during changing clothes or other decontamination procedures. Personal sampling, which would have given a clearer indication of the patient's actual exposure, was not performed.
Despite the lack of direct data, there are several indications that the patient was highly exposed. The strongest is the fact that the patient was positive for beryllium disease (CBD). Although this disease may occur in those with high exposures (6-9). Another indication that the patient was highly exposed is that his job duties were similar to those associated with high beryllium levels at other facilities. For example, airborne beryllium levels nearly 10 times the current threshold limit value were reported for metal casting in beryllium processing plants during the 1960s, the same period that our patient was most likely exposed (10,11).
Because the patient's duties involving asbestos were similar to those of asbestos insulators (i.e., the removal, cutting, and replacing of asbestos insulation), data from other sources could be used to estimate the patient's exposure to asbestos. Based on several exposure studies, Nicholson (12) estimated that average fibers counts for asbestos insulators before the 1970s were approximately 10-15 fiber/[cm.sup.3] (12). The similar period and comparable job duties suggest that this is a reasonable but likely high-range estimated of our patient's exposure.
Does beryllium cause cancer? The International Agency for Research on Cancer (IARC) considers beryllium definitely carcinogenic to humans (13). This classification is based primarily on two epidemiologic studies (14,15) shown in Table 1, which show small but consistent relative risk. Several earlier studies reported similar findings, but certain methodologically problems limited their ability to clarify this association (16-18). In addition to the human epidemiologic data, animal studies showing consistent dose-response increases of lung tumors in rats and evidence of carcinogenicity in several other species also support the link between beryllium and cancer (13,19). Despite these data, several authors have raised doubts that a causal association between beryllium and lung cancer truly exists (20-25). These doubts are primarily a result of criticisms aimed at the human epidemiologic data. More common criticisms include the lack of direct exposure data, unclear dose--response relationships, and insufficient control of potential confounding factors such as smoking.
Table 1. Selected studies of beryllium and lung cancer. Study Study design Results Steenland and Ward, For 689 people in a Lung cancer 1991 (14) beryllium case SMR = 2.00 (95% CI, registry, mortality 1.33-2.89; 28 experience in 1989 cases). For those was determined and with chronic compared to U.S. beryllium disease, rates. lung cancer SMR = 1.57 (95% CI, 0.75-2.89; 10 cases). Ward et al., Cohort study of 9,225 Respiratory cancer 1992 (15) males at seven SMR = 1.26 (95% CI, beryllium production 1.12-1.42; 280 or processing plants. cases). With crude adjustment for smoking, SMR = 1.13. For latency > 30 years since first employment, SMR = 1.46 (p < 0.01; 134 cases).
Abbreviations: CI, confidence interval; SMR, standardized mortality ratio.
For example, Steenland and Ward (14) collected smoking information on only 32% of the cohort. This 32% may not represent the entire cohort, and higher than predicted rates of smoking may actually be responsible for the effects attributed to beryllium. On the other hand, the overall smoking rates estimated for the cohort were already high (61% of the cohort were estimated to be former of current smokers compared to 65% for the age-sex-adjusted U.S. population), and there is no firm evidence to suggest that smoking rates were substantially higher than this. Even if they were, the smoking rate in the cohort would have to be twice as high as that in the reference population to be responsible for a relative risk of 2.0. It is hard to imagine that the rate of smoking within the study cohort was double that of the reference population when 65% of the reference population were current or former smokers.
Another criticism of the epidemiologic data linking beryllium to cancer is the supposed lack of clear dose-response relationships. For example, we normally expect to find a greater risk in workers who were exposed for longer periods of time, but Ward et al. (15) reported that the highest risks were found in workers with the shortest tenure. This is not necessarily inconsistent with a true dose response, however. Instead, it may be related to Ward et al.'s inclusion of both highly exposed manufacturing workers and lesser exposed administrative personnel. That is, an increased risk with shorter tenure may actually represent an increased exposure in workers with the most dusty and unpleasant jobs who were more likely to quit sooner. Unfortunately, there are no individual exposure data to confirm whether a true dose-response relationship does or does not exist.
The lack of individual exposure data has also been cited as a weakness in these studies. It should be noted that the exposure misclassification resulting from this lack of data is likely to be nondifferential. It would therefore typically bias the relative risk towards the null and not produce a spurious association (26,27). For example, the Ward et al.'s cohort included all workers in seven beryllium processing plants, so it likely included some unexposed administrative personnel (15). If this unexposed group were removed from the study, the relative risk might be greater. For example, if 30% of the cohort were unexposed administrative personnel, removing this group would increase the relative risk from 1.26 to approximately 1.40.
Although the evidence linking beryllium to cancer is somewhat controversial, dismissing beryllium as a potential carcinogen based on our current knowledge appears unwarranted, especially in light of the extensive animal data supporting this association.
Estimating risks. Because of the lack of quantifiable data, an accurate estimate of this patient's beryllium exposure is difficult to make. Even if his exposure could be precisely determined, the current literature provides very little dose-response data with which to make an accurate assessment of his risk. Given these limitations, the clearest indication of the patients' risk is provided by Steenland and Ward (14). This study shows that individuals with CBD had relative lung cancer mortality risks of approximately 1.5. This estimate is supported by Ward et al. (15). This study included all workers in a variety of different jobs with varied exposures to beryllium. Thus, the risks estimated from this study probably represent an average of highly exposed and minimally exposed workers. Our patient performed a variety of job duties, many of which were the same as those found in beryllium processing plants. Therefore, it could be argued that this exposures were probably similar to those of the Ward et al. cohort and that his subsequent risk of lung cancer was close to the relative risk of 1.5 which Ward et al. (15) reported for workers with latencies of over 30 years.
The patient's lung cancer risks from smoking appear to be quite similar to this estimate. As shown, in Figure 1, lung cancer risks in ex-smokers tend to gradually decline as the period of cessation increases (28-34). Although current smokers can have 20- to 30-fold higher risks of lung cancer than non-smokers, relative risks may drop below 2-fold 10-40 years after quitting. Our patient had a 22 pack-year smoking history, but quit smoking 36 years ago. Table 2 provides further details on the data from Figure 1 that best reflect this smoking history. Risks in these ex-smokers range from 1.07 to 2.10. Our patient's lung cancer risk from smoking is most likely somewhere between these values, and appears essentially indistinguishable from that estimated for his beryllium exposure.
[Figure 1 ILLUSTRATION OMITTED]
Table 2. Selected results from studies of lung cancer risks in former smokers.
Study Source Cederlof et al. (28) 55,000 Swedish citizens Doll and Peto (29) 34,440 British doctors, 1951-1971 Halpren et al. (30) ACS CPS II: 852,789 people from throughout the United States, 1982-1988 Hammond (31) ACS CPS I: 1,045,087 people in 25 states in the United States, 1959-1963 Higgins and Wynder (32) Case control study in six U.S. cities, 2,085 mate cases, 1977-1984 Rogot and Murray (33) 248,195 U.S. Veterans, 1954-1969 Wynder et al. (34) Case-control study in New York, 240 cases, 1966-1969 Years Cigarettes/ Study quit day RR Cases Cederlof et al. (28) 10+ NA 1.1 3 Doll and Peto (29) 15+ 9(a) 2.0 7 Halpren et al. (30) 40 26.4(a) 1.08 4 Hammond (31) 10+ 20+ 1.07 5 Higgins and Wynder (32) 30+ 11-20 1.8 7 Rogot and Murray (33) 20+ NA 2.10 123 Wynder et al. (34) 13+ NA 1.07 2
Abbreviations: ACS CPS, American Cancer Society Cancer Prevention Study; NA, not available; RR, estimated relative risk.
(a) Average for all age groups.
The patient's risk from asbestos seems to be lower than his risk attributable to tobacco smoke or beryllium. His exposures were probably on the order of 10-15 fibers/[cm.sup.3]. The patient worked with asbestos for approximately 10 years, but only for 1-2 hr/week or about 4% of his working time. Therefore, his cumulative exposure was probably near 4--6 fiber-years (10-15 fibers/[cm.sup.3] x 10 years x 4% time). It was estimated that cumulative lung cancer risk increases approximately 2% for each fiber-year of exposure (35). This suggests that the patient's lung cancer risk from asbestos was near a relative risk of 1.1, and was therefore probably less than his risk from beryllium or smoking.
On the basis of the patient's medical and occupational history, there was strong evidence that he was exposed to relatively high levels of both beryllium and tobacco smoke. There also seems to be little solid evidence to dismiss IARC's assertion that beryllium is carcinogenic (13), although some controversy exists over the quality of the available epidemiologic data. On the basis of our review of the literature, we estimated that the patient's lung cancer risk from beryllium was roughly the same as that from his smoking. If the patient had been a current smoker or recent ex-smoker, the patient's risk from smoking would have likely been much greater than his risk from beryllium. Because he had stopped smoking over 30 years before the diagnosis, however, we concluded that the patient's workplace experience, specifically his exposure to beryllium, was an important contributing factor to his development of lung cancer. Asbestos may have also contributed to the patient's disease, but his estimated risk from this carcinogen appears to be below that of beryllium and tobacco smoke.
Given the limited data available, the risk estimates described in this paper are obviously inexact. Nonetheless, occupational physicians are frequently asked to provide some input on cancer causation in smokers or ex-smokers exposed to occupational carcinogens such as beryllium and asbestos. This case provides an example of the use of data-based risk estimates to determine probable causation in the common scenario of limited epidemiologic and exposure information.
REFERENCES AND NOTES
(1.) Ritz B, Morgenstern H, Froines J, Young B. Effects of exposure to external ionizing radiation on cancer mortality in nuclear workers monitored for radiation at Rocketdyne/Atomics International. Am J Ind Med 35:21-31 (1999).
(2.) Fromme E, Cragle D, Watkins J, Wing S, Shy C, Tankersley W, West C. A mortality study of employees of the nuclear industry in Oak Ridge, Tennessee. Radiat Res 148:64-80 (1997).
(3.) Seiler D, Rice C, Herrick R, Hertzberg V. A study of beryllium exposure measurements: parts 1 and 2. Appl Occup Environ Hyg 11:89-102 (1996).
(4.) Bernard A, Torma-Krajewski J, Viet S. Retrospective beryllium exposure assessment at the Rocky Flats Environmental Site. Am Ind Hyg Assoc J 57:804-808 (1996).
(5.) Martyny J, Hoover M, Mroz M, Ellis K, Maier L, Sheff K, Newman L. Aerosols generated during beryllium machining. J Occup Environ Med 42:8-19 (2000).
(6.) Kreiss K, Mroz MM, Zhen B, Martyny JW, Newman LS. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis 148:985-991 (1993).
(7.) Kreiss K, Wasserman S, Mroz MM, Newman LS. Beryllium disease screening in the ceramics industry. Blood lymphocyte test performance and exposure-disease relations. J Occup Med 35:267-274 (1993).
(8.) Yoshida T, Shima S, Nagaoka K, Taniwaki H, Wada A, Kurita H, Morita K. A study on the beryllium lymphocyte transformation test and the beryllium levels in working environment. Ind Health 35:374-379 (1997).
(9.) Kreiss K, Mroz MM, Newman LS, Martyny J, Zhen B. Machining risk of beryllium disease and sensitization with median exposures below 2 micrograms/[m.sup.3]. Am J Industrial Med 30:16-25 (1996).
(10.) Kriebel D, Sprince N, Eisen E, Greaves I. Pulmonary function in beryllium workers: assessment of exposure. Br J Ind Med 45:83-92 (1988).
(11.) Cholack J, Schafer L, Yeager D. Exposures to beryllium in a beryllium alloying plant. Am Ind Hyg Assoc J 28:399-407 (1967).
(12.) Nicholson W. Case study 1: asbestos-the TLV approach. Ann NY Acad Sci 271:152-169 (1976).
(13.) International Agency for Research on Cancer. Beryllium, cadmium, mercury and exposures in the glass manufacturing industry. Monogr Eval Carcinog Risk Hum 58:41-117 (1993).
(14.) Steenland K, Ward E. Lung cancer incidence among patients with beryllium disease: a cohort mortality study. J Natl Cancer Inst 83:1380-1385 (1991).
(15.) Ward E, Okun A, Ruder A, Fingerhut M, Steenland K. A mortality study of workers at seven beryllium processing plants. Am J Ind Med 22:885-904 (1992).
(16.) Infante P, Wagoner J, Sprince N. Mortality patterns from lung cancer and nonneoplastic respiratory disease among white males in the Beryllium Case Registry. Environ Res 21:35-43 (1980).
(17.) Mancuso T. Mortality study of beryllium industry workers' occupational lung cancer. Environ Res 21:48-55 (1980).
(18.) Wagoner J, Infante P, Bayliss D. Beryllium: an etiologic agent in the induction of lung cancer, nonneoplastic respiratory disease and heart disease among industrially exposed workers. Environ Res 21:15-34 (1980).
(19.) Finch G, March T, Hahn F, Barr E, Belinsky S, Hoover M, Lechner J, Nikula K, Hobbs C. Carcinogenic responses of transgenic heterozygous p53 knockout mice to inhaled [sup.239]Pu[O.sub.2] or metallic beryllium. Toxicol Pathol 26:484-491 (1998).
(20.) Vainio H, Rice J. Beryllium revisted. J Occup Environ Med 39:203-204 (1997).
(21.) Eisenbud M. Re: Lung cancer incidence among patients with beryllium disease [Letter]. J Natl Cancer Inst 85:1697-1698 (1993).
(22.) Beryllium industry Scientific Advisory Committee. Is beryllium carcinogenic in humans. J Occup Environ Med 39:205-208 (1997).
(23.) Lang L. Beryllium: a chronic problem. Environ Health Perspect 102:526-531 (1994).
(24.) MacMahon B. The epidemiological evidence on the carcinogenicity of beryllium in humans. J Occup Med 36:15-24 (1994).
(25.) Saracci R. Beryllium and lung cancer: adding another piece to the puzzle of epidemiologic evidence. J Natl Cancer Inst 83:1362-1363 (1991).
(26.) Flegal K, Keyl P, Nieto F. Differential misclassification arising from non-differential errors in exposure measurement. Am J Epidemiol 134:1233-1244 (1991).
(27.) Rothman K, Greenland S. Precision and vailidity in epidemiological studies. In: Modern Epidemiology (Rothman K, Greenland S, eds). Philadelphia, PA:Lippencott-Raven Publishers, 1998;115-134.
(28.) Cederlof R, Friberg L, Hrubec Z, Lorich U. The Relationship of Smoking and Some Social Covariables to Mortality and Cancer Morbidity. A Ten Year Follow-up in a Probability Sample of 55,000 Swedish Subjects, Age 18-69. Parts 1 and 2. Stockholm:Department of Environmental Hygiene, The Karolinski Institute, 1975.
(29.) Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J 2:1525-1536 (1976).
(30.) Halpren M, Gillespie B, Warner K. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 85:457-464 (1993).
(31.) Hammond E. Smoking in relation to the death rates in one million men and women. NCI Monogr 19:127-204 (1966).
(32.) Higgins I, Wynder E. Reduction in risk of lung cancer among ex-smokers with particular reference to histologic type. Cancer 62:2397-2401 (1988).
(33.) Rogot E, Murray J. Smoking and causes of death among US veterans: 16 years of observation. Public Health Rep 95:213-222 (1980).
(34.) Wynder E, Mabuchi K, Beattie E. The epidemiology of lung cancer:, recent trends. JAMA 213:2221-2228 (1970).
(35.) Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health 23:311-316 (1997).
Craig Steinmaus and John R. Balmes
Division of Occupational and Environmental Medicine, Department of Medicine, University of California, San Francisco
Please address correspondence to C.M. Steinmaus, Allan Smith Research Office, School of Public Health, 140 Warren Hall, University of California, Berkeley, Berkeley, CA 94720-7360 USA. Telephone 510 843-1736. Fax: 510 843-5539. E-mail: email@example.com
This work was supported by the University of California Center for Occupational and Environmental Health. Additional support was provide by grant 1-RO1-ESO7459-01A2 from the National Institute of Environmental Health Sciences and grant 99-00563V-10262 from the California Cancer Research Program.
Received 24 March 2000; accepted 11 July 2000.
|Printer friendly Cite/link Email Feedback|
|Author:||Balmes, John R.|
|Publication:||Environmental Health Perspectives|
|Date:||Oct 1, 2000|
|Previous Article:||Evaluation and Use of Epidemiological Evidence for Environmental Health Risk Assessment: WHO Guideline Document.|
|Next Article:||Extramurally Speaking ...|